284 related articles for article (PubMed ID: 22841559)
1. Increased incidence of cutaneous squamous cell carcinoma in lung transplant recipients taking long-term voriconazole.
Feist A; Lee R; Osborne S; Lane J; Yung G
J Heart Lung Transplant; 2012 Nov; 31(11):1177-81. PubMed ID: 22841559
[TBL] [Abstract][Full Text] [Related]
2. Voriconazole exposure and geographic location are independent risk factors for squamous cell carcinoma of the skin among lung transplant recipients.
Vadnerkar A; Nguyen MH; Mitsani D; Crespo M; Pilewski J; Toyoda Y; Bermudez C; Kwak EJ; Silveira FP; Clancy CJ
J Heart Lung Transplant; 2010 Nov; 29(11):1240-4. PubMed ID: 20591690
[TBL] [Abstract][Full Text] [Related]
3. Risk-adjusted relationship between voriconazole utilization and non-melanoma skin cancer among lung and heart/lung transplant patients.
McLaughlin JM; Equils O; Somerville KT; Aram JA; Schlamm HT; Welch VL; Mardekian J; Barbers RG
Transpl Infect Dis; 2013 Aug; 15(4):329-43. PubMed ID: 23489832
[TBL] [Abstract][Full Text] [Related]
4. Duration of voriconazole exposure: an independent risk factor for skin cancer after lung transplantation.
Zwald FO; Spratt M; Lemos BD; Veledar E; Lawrence C; Marshall Lyon G; Chen SC
Dermatol Surg; 2012 Aug; 38(8):1369-74. PubMed ID: 22551390
[TBL] [Abstract][Full Text] [Related]
5. High cumulative dose exposure to voriconazole is associated with cutaneous squamous cell carcinoma in lung transplant recipients.
Singer JP; Boker A; Metchnikoff C; Binstock M; Boettger R; Golden JA; Glidden DV; Arron ST
J Heart Lung Transplant; 2012 Jul; 31(7):694-9. PubMed ID: 22484291
[TBL] [Abstract][Full Text] [Related]
6. Multifocal squamous cell carcinomas in an HIV-infected patient with a long-term voriconazole therapy.
Brunel AS; Fraisse T; Lechiche C; Pinzani V; Mauboussin JM; Sotto A
AIDS; 2008 Apr; 22(7):905-6. PubMed ID: 18427212
[No Abstract] [Full Text] [Related]
7. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML).
Vehreschild JJ; Böhme A; Buchheidt D; Arenz D; Harnischmacher U; Heussel CP; Ullmann AJ; Mousset S; Hummel M; Frommolt P; Wassmer G; Drzisga I; Cornely OA
J Infect; 2007 Nov; 55(5):445-9. PubMed ID: 17822770
[TBL] [Abstract][Full Text] [Related]
8. Multiple aggressive squamous cell carcinomas associated with prolonged voriconazole therapy in four immunocompromised patients.
Epaulard O; Saint-Raymond C; Villier C; Charles J; Roch N; Beani JC; Leccia MT
Clin Microbiol Infect; 2010 Sep; 16(9):1362-4. PubMed ID: 19930272
[TBL] [Abstract][Full Text] [Related]
9. Cutaneous squamous cell carcinoma in two pediatric lung transplant patients on prolonged voriconazole treatment.
Wong JY; Kuzel P; Mullen J; Lien D; Mahmood M; Conrad C; Fiorillo L
Pediatr Transplant; 2014 Sep; 18(6):E200-7. PubMed ID: 25039541
[TBL] [Abstract][Full Text] [Related]
10. Mold infections in lung transplant recipients.
Bhaskaran A; Hosseini-Moghaddam SM; Rotstein C; Husain S
Semin Respir Crit Care Med; 2013 Jun; 34(3):371-9. PubMed ID: 23821511
[TBL] [Abstract][Full Text] [Related]
11. Phototoxicity and photocarcinogenesis associated with voriconazole.
Epaulard O; Leccia MT; Blanche S; Chosidow O; Mamzer-Bruneel MF; Ravaud P; Thiebaut A; Villier C; Lortholary O
Med Mal Infect; 2011 Dec; 41(12):639-45. PubMed ID: 22055586
[TBL] [Abstract][Full Text] [Related]
12. Severe photosensitivity causing multifocal squamous cell carcinomas secondary to prolonged voriconazole therapy.
McCarthy KL; Playford EG; Looke DF; Whitby M
Clin Infect Dis; 2007 Mar; 44(5):e55-6. PubMed ID: 17278050
[TBL] [Abstract][Full Text] [Related]
13. Incidence and risk factors for skin cancer following lung transplantation.
Rashtak S; Dierkhising RA; Kremers WK; Peters SG; Cassivi SD; Otley CC
J Am Acad Dermatol; 2015 Jan; 72(1):92-8. PubMed ID: 25440431
[TBL] [Abstract][Full Text] [Related]
14. Use of prophylactic voriconazole for three months after lung transplantation does not reduce infection with Aspergillus: a retrospective study of 147 patients.
Tofte N; Jensen C; Tvede M; Andersen CB; Carlsen J; Iversen M
Scand J Infect Dis; 2012 Nov; 44(11):835-41. PubMed ID: 22803836
[TBL] [Abstract][Full Text] [Related]
15. Voriconazole increases the risk for cutaneous squamous cell carcinoma after lung transplantation.
Kolaitis NA; Duffy E; Zhang A; Lo M; Barba DT; Chen M; Soriano T; Hu J; Nabili V; Saggar R; Sayah DM; DerHovanessian A; Shino MY; Lynch JP; Kubak BM; Ardehali A; Ross DJ; Belperio JA; Elashoff D; Saggar R; Weigt SS
Transpl Int; 2017 Jan; 30(1):41-48. PubMed ID: 27678492
[TBL] [Abstract][Full Text] [Related]
16. Voriconazole and the Risk of Keratinocyte Carcinomas Among Lung Transplant Recipients in the United States.
D'Arcy ME; Pfeiffer RM; Rivera DR; Hess GP; Cahoon EK; Arron ST; Brownell I; Cowen EW; Israni AK; Triplette MA; Yanik EL; Engels EA
JAMA Dermatol; 2020 Jul; 156(7):772-779. PubMed ID: 32401271
[TBL] [Abstract][Full Text] [Related]
17. Preemptive treatment with voriconazole in lung transplant recipients.
Neoh CF; Snell GI; Levvey B; Kotsimbos T; Morrissey CO; Slavin MA; Stewart K; Kong DC
Transpl Infect Dis; 2013 Aug; 15(4):344-53. PubMed ID: 23527908
[TBL] [Abstract][Full Text] [Related]
18. Voriconazole-associated phototoxicity.
Riahi RR; Cohen PR
Dermatol Online J; 2011 Feb; 17(2):15. PubMed ID: 21382298
[TBL] [Abstract][Full Text] [Related]
19. [Careful: skins cancers and voriconazole].
Schmutz JL; Trechot P
Ann Dermatol Venereol; 2011 Nov; 138(11):805-6. PubMed ID: 22078051
[No Abstract] [Full Text] [Related]
20. Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis.
Thomas A; Korb V; Guillemain R; Caruba T; Boussaud V; Billaud E; Prognon P; Begué D; Sabatier B
J Clin Pharm Ther; 2010 Feb; 35(1):49-53. PubMed ID: 20175811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
